Cargando…

The Impact of COVID-19 Vaccination on Inflammatory Skin Disorders and Other Cutaneous Diseases: A Review of the Published Literature

Background: Four vaccines have been authorized by the European Medicines Agency (EMA): viral vector-based vaccines (AstraZeneca; AZD1222 and Johnson & Johnson; Ad26.COV2. and 2 mRNA-based vaccines (Pfizer/BioNTech; BNT162b2 and Moderna; mRNA-1273). Adverse events (AEs) related to vaccination hav...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martora, Fabrizio, Battista, Teresa, Ruggiero, Angelo, Scalvenzi, Massimiliano, Villani, Alessia, Megna, Matteo, Potestio, Luca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10384785/ https://www.ncbi.nlm.nih.gov/pubmed/37515110 http://dx.doi.org/10.3390/v15071423

Ejemplares similares

Hidradenitis Suppurativa and JAK Inhibitors: A Review of the Published Literature
por: Martora, Fabrizio, et al.
Publicado: (2023)

Teledermatology for Common Inflammatory Skin Conditions: The Medicine of the Future?
por: Martora, Fabrizio, et al.
Publicado: (2023)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
por: Martora, Fabrizio, et al.
Publicado: (2023)

Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments
por: Battista, Teresa, et al.
Publicado: (2023)

Herpes Zoster and COVID-19 Vaccination: A Narrative Review
por: Potestio, Luca, et al.
Publicado: (2023)

COVID‐19 vaccination and inflammatory skin diseases
por: Martora, Fabrizio, et al.
Publicado: (2022)

COVID‐19 and cutaneous manifestations: A review of the published literature
por: Martora, Fabrizio, et al.
Publicado: (2022)

Effectiveness and Safety of Deucravacitinib for the Management of Psoriasis: A Review of the Current Literature
por: Potestio, Luca, et al.
Publicado: (2023)

Use of Biological Therapies for the Management of Pustular Psoriasis: A New Era?
por: Megna, Matteo, et al.
Publicado: (2023)

New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge
por: Potestio, Luca, et al.
Publicado: (2023)

Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
por: Potestio, Luca, et al.
Publicado: (2023)

Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience
por: Martora, Fabrizio, et al.
Publicado: (2023)

Safety and Efficacy of Covid-19 Vaccination in Patients Undergoing Biological Treatments for Psoriasis
por: Potestio, Luca, et al.
Publicado: (2023)

The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Management of Advanced Invasive Melanoma: New Strategies
por: Villani, Alessia, et al.
Publicado: (2023)

Efficacy and Safety of Tildrakizumab in a Patient with Chronic HBV Infection
por: Potestio, Luca, et al.
Publicado: (2023)

Development of a Patient-Reported Outcome Measure (PROM) for Dysgeusia During Treatment With Smoothened (SMO) Inhibitors for Basal Cell Carcinomas: The SMO-iD Questionnaire
por: Camela, Elisa, et al.
Publicado: (2023)

Guselkumab-induced vitiligo in a patient with psoriatic arthritis
por: Martora, Fabrizio, et al.
Publicado: (2023)

Cutaneous Reactions Following COVID-19 Vaccination: A Review of the Current Literature
por: Martora, Fabrizio, et al.
Publicado: (2022)

Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
por: Cacciapuoti, Sara, et al.
Publicado: (2023)

Long-Term Efficacy and Safety of Risankizumab for Moderate to Severe Psoriasis: A 2-Year Real-Life Retrospective Study
por: Megna, Matteo, et al.
Publicado: (2023)

A case of scalp psoriasis resistant to ixekizumab treated with bimekizumab
por: Megna, Matteo, et al.
Publicado: (2023)

New Emerging Treatment Options for Advanced Basal Cell Carcinoma and Squamous Cell Carcinoma
por: Villani, Alessia, et al.
Publicado: (2022)

Community Knowledge About the Use, Reuse, Disinfection and Disposal of Masks and Filtering Facepiece Respirators: Results of a Study Conducted in a Dermatology Clinic at the University of Naples in Italy
por: Scalvenzi, Massimiliano, et al.
Publicado: (2020)

Sonidegib with and Without Adjunctive Treatment for Locally Advanced Basal Cell Carcinomas
por: Villani, Alessia, et al.
Publicado: (2022)

Concomitant Severe Psoriasis and Bullous Pemphigoid Induced by COVID-19
por: Martora, Fabrizio, et al.
Publicado: (2023)

A case of linear psoriasis in a young patient with Down syndrome and review of the literature
por: Martora, Fabrizio, et al.
Publicado: (2022)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Long‐term results of teledermatology for acne patients during COVID‐19 pandemic
por: Villani, Alessia, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study
por: Megna, Matteo, et al.
Publicado: (2022)

The Treatment of Advanced Melanoma: Therapeutic Update
por: Villani, Alessia, et al.
Publicado: (2022)

The Efficacy of Sonidegib in Treating Locally Advanced Basal Cell Carcinoma Involving the Periocular Area
por: Villani, Alessia, et al.
Publicado: (2023)

A case of severe psoriatic arthritis with hands flexion contracture and palmar psoriasis successfully treated with guselkumab
por: Megna, Matteo, et al.
Publicado: (2022)

Pemphigus vulgaris and COVID‐19 vaccination: Management and treatment
por: Martora, Fabrizio, et al.
Publicado: (2022)

Long‐term efficacy of telemedicine for patients with locally advanced basal cell carcinoma during COVID‐19 pandemic
por: Villani, Alessia, et al.
Publicado: (2022)

Teledermatology in the management of hidradenitis suppurativa: Should we improve this service?
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge
por: Ruggiero, Angelo, et al.
Publicado: (2022)

Risankizumab treatment in psoriasis patients who failed anti‐IL17: A 52‐week real‐life study
por: Megna, Matteo, et al.
Publicado: (2022)

Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting
por: Megna, Matteo, et al.
Publicado: (2022)

Teledermatology: A useful tool also after COVID‐19 era?
por: Megna, Matteo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ss0dovn7fvgm4mqsc6dplgijm4